Dry Eye Disease - Pipeline Insight, 2024

This “Dry Eye Disease - Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dry Eye Disease: Understanding

Dry Eye Disease: Overview

Dry eye is a chronic and sometimes debilitating disease resulting from tear film dysfunction. Dry eye disease (DED) is a complex, multifactorial condition characterized by inflammation of the ocular surface and lacrimal glands and reductions in the quality and/or quantity of tears. As per National Eye Institue,the new definition of dry eye is “Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”

DED has traditionally been classified into two categories: aqueous deficient and evaporative. These two categories, however, are not mutually exclusive, and numerous patients have a combination of these mechanisms of DED. Aqueous tear deficiency is characterized by inadequate tear production with predominant causes consisting of Sjogren Syndrome (primary or secondary); diseases, inflammation, and/or dysfunction of the lacrimal gland; obstruction of the lacrimal gland; and systemic drugs (i.e., decongestants, antihistamines, diuretics, beta-blockers, etc.) Evaporative dry eye is characterized by increased tear film evaporation and a deficiency in the lipid portion of the tear film. In this case, the quantity of tears produced is normal; however, the quality of tears causes excessive evaporation. This alteration is most frequently caused by meibomian gland dysfunction.

Treatment of dry eye syndrome is performed in a step-wise approach that may vary depending on the severity of the disease. Initial approaches include education about the condition, modification of the environment (eliminating direct high airflow/fans, reduced screen time, humidifier), identification and elimination of offending topical and systemic agents, topical ocular lubricants, and lid hygiene (warm compresses and lid scrubs), oral essential fatty acids.

The next step of treatment options includes preservative-free ocular lubricants, reversible punctal occlusion (punctal plugs), night-time ointment or moisture goggles, device-assisted heating and/or expression of the meibomian glands, intense pulsed light therapy, topical anti-inflammatory medications (corticosteroids, cyclosporine, lifitegrast), and oral antibiotics (macrolide or tetracycline).

"Dry Eye Disease - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.

Dry Eye Disease Emerging Drugs Chapters

This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dry Eye Disease Emerging Drugs

AR-15512: Alcon

AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of DED.

HU007: Huons

HU007 is a combination of cyclosporine, an anti-inflammatory component, and trehalose, a tear film protection component, to minimize eye surface irritation such as burning sensation by lowering the concentration of cyclosporine to less than half than that of existing treatments. In addition, it is an ophthalmic agent developed to suppress the destruction of each conjunctival epithelial cells caused by drying by combining trehalose preparations and to see the combined treatment effect for dry eyes. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

A197: Aramis Biosciences

A197 is a novel topical agent that targets the immunopathogenesis of dry eye disease. It has a unique mechanism of action compared to existing dry eye treatments. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

INV 102: Invirsa, Inc.

INV 102 is an ophthalmic eye drop being developed by Invirsa, Inc. Invirsa’s lead candidate is a naturally-occurring, small molecule that modulates the activity of p53, the central protein responsible for regulating the DNA damage response. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

iVIEW 1001: IVIEW Therapeutics

iVIEW 1001 is a TRPM8 agonist drug being developed by iVIEW Therapeutics, Inc. to treat dry eye diseases. IVIEW 1001 is a TRPM8 agonist, which means it stimulates the transient receptor potential melastatin 8 (TRPM8) receptors in the eyelid margin. This stimulation sends a perception of coolness, reducing ocular discomfort and potentially increasing tear secretion. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

Dry Eye Disease: Therapeutic Assessment

This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dry Eye Disease

There are approx. 45+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. Phase III include, Alcon, Huons, and others.

Phases

The report covers around 50+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dry Eye Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs.

Dry Eye Disease Report Insights

• Dry Eye Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dry Eye Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dry Eye Disease drugs?
• How many Dry Eye Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dry Eye Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Alcon
• Seikagaku Corporation
• Huons
• Aramis Biosciences
• Invirsa, Inc.
• IVIEW Therapeutics
• Seinda Pharmaceutical
• Serentrix
• EyeD Pharma
• SELAGINE
• Theratome Bio
• Alchemedicine

Key Products

• AR-15512
• SI-614
• HU007
• A197
• INV 102
• iVIEW 1001
• SY-201
• SER-114
• HydraD
• SLG-100
• Thera 102
• Dry eye disease therapeutic

This product will be delivered within 2-4 business days.